DRMA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	276 446
Average Volume	160 022
Market Cap	2.25M
EPS	$0 ( 2024-02-20 )
Next earnings date	( $-0.360 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0.00400 (1.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-04	Mento Steven J	Buy	10 000	Stock Option (Right to Buy)
2024-01-04	Proehl Gerald T	Buy	125 000	Stock Option (right to buy)
2024-01-04	Fisher Mary	Buy	10 000	Stock Option (Right to Buy)
2024-01-04	Scott Kathleen D.	Buy	10 000	Stock Option (Right to Buy)
2024-01-04	Sandler Andrew Seth	Buy	10 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 98 transactions
Buy: 8 169 572 \| Sell: 872 238

Volume Correlation

Long: 0.09 (neutral)

Short: -0.41 (neutral)

Signal:(46.3) Neutral

Dermata Therapeutics, Correlation

10 Most Positive Correlations
SVAC	0.964
PAIC	0.955
TLGT	0.926
SVOK	0.917
RMRM	0.917
SPRT	0.885
EARS	0.875
PROG	0.873
BLPH	0.863
FORE	0.859

10 Most Negative Correlations
NETE	-0.977
AMRB	-0.924
MMAC	-0.903
RAVN	-0.892
SRAC	-0.88
ANIK	-0.866
BOCH	-0.85
ATHN	-0.849
CPTN	-0.839
ODT	-0.835

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Dermata Therapeutics, Correlation - Currency/Commodity

-0.06
( neutral )

0.14
( neutral )

0.00
( neutral )

-0.78
( moderate negative )

0.00
( neutral )

0.59
( weak )

Dermata Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.67

Q4	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.540

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.540

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.630

Financial Reports:

No articles found.

Dermata Therapeutics,

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.